34 related articles for article (PubMed ID: 8971387)
1. Graft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission: autologous LAK cells following allogeneic bone marrow transplantation are donor-derived.
Boughton BJ; Simpson AW; Phaure TA; Beatty C
Cancer Immunol Immunother; 1995 Jul; 41(1):68-70. PubMed ID: 7641221
[TBL] [Abstract][Full Text] [Related]
2. The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.
Maurer K; Antin JH
Front Immunol; 2024; 15():1328858. PubMed ID: 38558819
[TBL] [Abstract][Full Text] [Related]
3. Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans.
Robin M; Schlageter MH; Chomienne C; Padua RA
Cancer Immunol Immunother; 2005 Oct; 54(10):933-43. PubMed ID: 15889256
[TBL] [Abstract][Full Text] [Related]
4. Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC).
Nagler A; Condiotti R; Rabinowitz R; Schlesinger M; Nguyen M; Terstappen LW
Med Oncol; 1999 Sep; 16(3):177-87. PubMed ID: 10523797
[TBL] [Abstract][Full Text] [Related]
5. T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia.
Jiang YZ; Cullis JO; Kanfer EJ; Goldman JM; Barrett AJ
Bone Marrow Transplant; 1993 Feb; 11(2):133-8. PubMed ID: 8435662
[TBL] [Abstract][Full Text] [Related]
6. [Successful treatment of recurrent chronic myelogenous leukemia in allogeneic marrow transplant recipient with the donor leukocyte transfusion, without induction of acute graft-versus-host disease].
Yamazaki H; Nakao S; Takamatsu H; Ito T; Ueda M; Shiobara S; Matsuda T
Rinsho Ketsueki; 1995 Jul; 36(7):677-81. PubMed ID: 7563596
[TBL] [Abstract][Full Text] [Related]
7. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
9. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
[TBL] [Abstract][Full Text] [Related]
10. Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation.
Kapelushnik J; Nagler A; Or R; Naparstek E; Ackerstein A; Samuel S; Morecki S; Nabet C; Slavin S
Bone Marrow Transplant; 1996 Dec; 18(6):1153-6. PubMed ID: 8971387
[TBL] [Abstract][Full Text] [Related]
11. Experimental evidence of interleukin-2 activity in bone marrow transplantation.
Mazumder A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S37-42. PubMed ID: 9457392
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
